

This is a repository copy of *Diagnostic accuracy of handheld cardiac ultrasound device for* assessment of left ventricular structure and function: systematic review and meta-analysis.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/177249/

Version: Published Version

Article:

Jenkins, S., Alabed, S. orcid.org/0000-0002-9960-7587, Swift, A. et al. (10 more authors) (2021) Diagnostic accuracy of handheld cardiac ultrasound device for assessment of left ventricular structure and function: systematic review and meta-analysis. Heart, 107 (22). pp. 1826-1834. ISSN 1355-6037

https://doi.org/10.1136/heartjnl-2021-319561

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.





Original research

Diagnostic accuracy of handheld cardiac ultrasound device for assessment of left ventricular structure and function: systematic review and meta-analysis

Sam Jenkins ⁽¹⁾, ¹ Samer Alabed ⁽¹⁾, ¹ Andrew Swift, ² Gabriel Marques, ³ Alisdair Ryding, ³ Chris Sawh, ³ James Wardley, ³ Benoy Nalin Shah ⁽¹⁾, ⁴ Peter Swoboda, ⁵ Roxy Senior ⁽¹⁾, ⁶ Robin Nijveldt, ⁷ Vassilios S Vassiliou ⁽¹⁾, ⁸ Pankaj Garg³

ABSTRACT

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/heartjnl-2021-319561).

¹Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK ²Cardiovascular and Metabolic Health, Academic Unit of Radiology, University of Sheffield, Sheffield, UK ³Cardiology, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK ⁴Cardiology, Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK ⁵LICAMM, University of Leeds, Leeds. UK ⁶Department of Cardiology, Royal Brompton Hospital, London, UK ⁷Vrije Universiteit Amsterdam, Amsterdam, The Netherlands ⁸Second Floor, Norwich Medical School, University of East Anglia, Norwich, UK

Correspondence to

Dr Pankaj Garg, Cardiology, Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UQ, Norfolk, UK; P.Garg@uea.ac.uk

Received 20 April 2021 Accepted 12 July 2021

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

To cite: Jenkins S, Alabed S, Swift A, *et al. Heart* Epub ahead of print: [*please include* Day Month Year]. doi:10.1136/ heartjnl-2021-319561 **Objective** Handheld ultrasound devices (HUD) has diagnostic value in the assessment of patients with suspected left ventricular (LV) dysfunction. This meta-analysis evaluates the diagnostic ability of HUD compared with transthoracic echocardiography (TTE) and assesses the importance of operator experience.

Methods MEDLINE and EMBASE databases were searched in October 2020. Diagnostic studies using HUD and TTE imaging to determine LV dysfunction were included. Pooled sensitivities and specificities, and summary receiver operating characteristic curves were used to determine the diagnostic ability of HUD and evaluate the impact of operator experience on test accuracy.

Results Thirty-three studies with 6062 participants were included in the meta-analysis. Experienced operators could predict reduced LV ejection fraction (LVEF), wall motion abnormality (WMA), LV dilatation and LV hypertrophy with pooled sensitivities of 88%, 85%, 89% and 85%, respectively, and pooled specificities of 96%, 95%, 98% and 91%, respectively. Non-experienced operators are able to detect cardiac abnormalities with reasonable sensitivity and specificity. There was a significant difference in the diagnostic accuracy between experienced and inexperienced users in LV dilatation, LVEF (moderate/severe) and WMA. The diagnostic OR for LVEF (moderate/severe). LV dilatation and WMA in an experienced hand was 276 (95% CI 58 to 1320), 225 (95% CI 87 to 578) and 90 (95% CI 31 to 265), respectively, compared with 41 (95% CI 18 to 94), 45 (95% CI 16 to 123) and 28 (95% CI 20 to 41), respectively, for inexperienced users.

Conclusion This meta-analysis is the first to establish HUD as a powerful modality for predicting LV size and function. Experienced operators are able to accurately diagnose cardiac disease using HUD. A cautious, supervised approach should be implemented when imaging is performed by inexperienced users. This study provides a strong rationale for considering HUD as an auxiliary tool to physical examination in secondary care, to aid clinical decision making when considering referral for TTE.

Trial registration number CRD42020182429.

INTRODUCTION

Echocardiography is the first-line imaging modality for assessing cardiac size and function. Indications

for transthoracic echocardiography (TTE) as recommended by the British Society of Echocardiography and other international societies include but not limited to: murmur in the presence of cardiac or respiratory symptoms, valvular stenosis or regurgitation, ischaemic heart disease, any suspicion of heart failure (HF) and arrhythmias.^{1–3} TTE allows determination of left ventricular (LV) dysfunction by assessing LV cavity size, wall thickness, valvular appearances and function as well as for the presence of abnormal blood flow within the heart.⁴

The miniaturisation of ultrasound technology has led to the introduction of handheld cardiac ultrasound devices (HUD).⁵ The portability and accessibility of HUD allow for the augmentation of the bedside physical examination. While physical examination remains the primary method for screening cardiovascular disease, the quality and subsequent referral to echocardiography depend on the examiner's experience and skill, or lack thereof.⁶ HUD therefore can bridge the gap between the physical examination and the more costly and timeconsuming departmental TTE.

Several recent studies have assessed the performance of HUD in diagnosing cardiac disease. The aim of this systematic review and meta-analysis is to assess the diagnostic accuracy of HUD to detect LV abnormalities when compared with TTE in both experienced and non-experienced users.

METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Cochrane Handbook of Diagnostic Test Accuracy were followed in the study selection, review process and evidence synthesis.^{7 8}

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Eligibility criteria

Any study comparing the diagnostic performance of HUD and TTE was eligible. The index test was any type or size of a HUD performed by operators of any level of experience. The reference standard was

Jenkins S, et al. Heart 2021;0:1–9. doi:10.1136/heartjnl-2021-319561



Heart failure and cardiomyopathies

TTE performed by experienced imagers. Studies were included if subjects were aged >18 years, sensitivity, specificity, true positive and negative and false positive and negative findings were reported or if diagnostic data could be extrapolated from the results. Studies with a sample size of <20 participants were excluded.

Search strategy and study selection

MEDLINE (ProQuest, 1946 to 13 October 2020), EMBASE (Ovid, 1974–2020 week 42) were searched on 13 October 2020. No search filters were applied. The full search strategy is available in the online supplemental document. The references of the included studies were also screened for relevant studies.

Two authors (SJ and PG) screened the titles and abstracts and reviewed full texts for inclusion criteria. Any disagreements were discussed with a third author (SA). Data extraction and risk of bias analysis was performed by two authors (SJ and PG) and disagreements discussed with a third author (SA). Methods for the quality assessment of individual studies are detailed in online supplemental figure 1.

Statistical analysis

A bivariate random-effects model was used to obtain the summary point for the sensitivity and specificity and estimate the corresponding 95% CI and prediction regions for all metaanalyses including four or more studies. The metandi command in Stata V.16 (StataCorp, College Station, Texas, USA) was used to perform the analyses and create summary receiver operating characteristics (SROC). The mada package in R was used to calculate the diagnostic ORs (DORs) for each study and the summary DOR for the pooled results with their respective 95% CIs (R Core Team, R: A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing, 2020). The Wilson method was used to calculate the CIs for sensitivities, specificities and false positive rates. The Yates correction was used for testing the equality of sensitivities and specificities. The input for the mada command was the number of true positives (TP), false negatives (FN), true negatives (TN) and false postives (FP) for each study.

The effect of operator experience on the effect size of the diagnostic accuracy was assessed in a subgroup analysis and graphically represented in SROC curves comparing the diagnostic accuracy of experienced and inexperienced operators. A meta-regression was also performed to assess the effect of operator experience.

RESULTS

Search results

Our comprehensive search identified 33 studies which were incorporated into the meta-analysis. The results of the literature search are outlined in the study flow diagram (figure 1).

Description of included studies

All studies had a prospective design, with consecutive or random patient selection reported in 21 studies. The studies were published between 2002 and 2019. The majority of studies (22 studies) had a large sample size ≥ 100 participants, with the largest study by Galasko *et al*⁸ recruiting 562 patients.⁹ Individual study data incorporated into the meta-analysis can be found in online supplemental table 1 and a summary graph of the overall risk of bias is shown in online supplemental figure 1.




Figure 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of literature search.

Study characteristics

A total of 6062 patients conducted in 13 different countries were included in the meta-analysis. The mean age of patients was 65 ± 5 years with a slight male predominance (54%). Study characteristics are presented in table 1. Study-level HUD data including sensitivity and specificity to predict reduced LV ejection fraction (LVEF), wall motion abnormality (WMA), LV dilatation and hypertrophy (LVH) are reported in the online supplemental materials.

Assessment of methodological quality

The majority of studies (19/25) reported a prospective and consecutive or random design. Only one study reported that HUD assessors were unblinded to TTE results while three studies were judged to incorporate a high risk of bias with TTE assessors unblinded to HUD results. There was some concern for bias when time between HUD and TTE was >48 hours. One study was judged to have a high risk of bias as time between HUD and TTE was >7 days.¹⁰ The detailed results of the quality assessment are outlined in online supplemental figure 2.

Meta-analysis of HUD indices

Each characteristic was separated into subgroups based on the investigator's level of experience. Inexperienced operators were those that learnt HUD as part of the study with limited or no prior echocardiography experience. This subgroup included nurses, medical students, residents, general practitioners and inexperienced cardiology trainees. Experienced operators were those who had undergone level II/III echocardiography training or who were stated to be experienced, expert, or trained in echocardiography.

Experienced operators could determine reduced LVEF, LV dilatation, WMA and LVH with pooled sensitivities of 88%, 89%, 85% and 85%, respectively (figures 2–4). In inexperienced hands, pooled sensitivities measured were 83%, 68%, 78% and 80%, respectively. Pooled specificities of HUD by experienced

Study	Country	Design	Study period	Size	Male (%)	Age, years	Level of experience	HUD
Aldaas <i>et al</i> ²¹	USA	Consecutive	NR	70	50	61±18	Both	Vscan
Alexander <i>et al</i> ²²	USA	NR	April–November 2000	537	53	59	Inexperienced	Optigo
Andersen <i>et al</i> ²³	Norway	Random	March–September 2010	108	64	69.1±14	Experienced	Vscan
Biais <i>et al²⁴</i>	France	Consecutive	February–May 2011	151	35	55±20	Experienced	Vscan
Bruce <i>et al⁹</i>	USA	NR	NR	374	62	66	Both	SonoHeart
Coletta <i>et al²⁵</i>	Italy	Consecutive	April–June 2003	112	57	61±11	Experienced	Optigo
Cullen <i>et al</i> ²⁶	USA	Consecutive	2012-2013	190	49	62±17	Experienced	Vscan
DeCara <i>et al²⁷</i>	USA	NR	NR	300	NR	NR	Experienced	Optigo
Fedson <i>et al²⁸</i>	USA	Consecutive	NR	103	NR	NR	Inexperienced	Optigo
Galasko ⁸	UK	Consecutive	2000–2001	562	56	62±11	Experienced	Optigo
Ghani <i>et al²⁹</i>	USA	Consecutive	NR	80	51	75±13	Inexperienced	Optigo
Giusca <i>et al³⁰</i>	Romania	Consecutive	NR	56	54	60±12	Inexperienced	Acuson P10
Gulič <i>et al³¹</i>	Slovenia	Consecutive	NR	200	43	70	Both	Vscan
Khan ³²	USA	Consecutive	2012–2013	240	53	71±17	Experienced	Vscan
Kirkpatrick ³³	USA	NR	NR	63	46	65±16	Inexperienced	Optigo
Kobal <i>et al³⁴</i>	USA	Consecutive	NR	61	62	70±19	Inexperienced	Optigo
Liebo ³⁵	USA	Consecutive	February–March 2010	97	45	68±17	Both	Vscan
López-Palmero <i>et al³⁶</i>	Spain	NR	July–December 2013	223	42	76	Inexperienced	Vscan
Lucas <i>et al³⁷</i>	USA	Consecutive	March–May 2007	322	53	56±13	Inexperienced	Micromaxx
Lucas <i>et al³⁸</i>	USA	Consecutive	2008–2009	210	55	55	Inexperienced	NR
Martin <i>et al³⁹</i>	USA	Consecutive	2004–2005	354	47	63±19	Inexperienced	Sonosite Elite
Mehta <i>et al</i> ⁴⁰	USA	NR	NR	250	66	61±15	Experienced	Vscan
Mjølstad <i>et al⁴¹</i>	Norway	Consecutive	April–June 2011	199	54	66±18	Inexperienced	Vscan
Nilsson <i>et al⁴²</i>	Sweden	NR	2016–2017	100	55	70±12	Inexperienced	Vscan
Olesen ⁴³	Denmark	NR	NR	260	49	80	Experienced	Vscan
Perez-Avraham <i>et al</i> ⁴⁴	Israel	Consecutive	July–December 2004	85	37	59±14	Inexperienced	Optigo
Razi <i>et al⁴⁵</i>	USA	Consecutive	NR	50	58	57±17	Inexperienced	Vscan
Ruddox <i>et al</i> ⁴⁶	Norway	NR	2011-2012	303	61	73	Inexperienced	Vscan
Stokke <i>et al</i> ¹³	Norway	Random	February–May 2012	72	72	65±16	Both	Vscan
Vignon <i>et al⁴⁷</i>	France	Consecutive	NR	55	69	61±16	Experienced	SonoHeart
Vourvouri <i>et al</i> ⁴⁸	The Netherlands	Consecutive	NR	88	64	59±12	Experienced	SonoHeart or Optig
Wejner-Mik <i>et al</i> ⁴⁹	Poland	Consecutive	NR	87	67	61±16	Experienced	Lumify
Xie <i>et al⁵⁰</i>	USA	Consecutive	NR	100	55	59±17	Experienced	SonoHeart

HUD, handheld ultrasound devices; NR, not reported.

users compared with inexperienced users for reduced LVEF, LV dilatation, WMA and LVH measured 96% vs 89%, 98% vs 95%, 95% vs 88% and 91% vs 87%. Online supplemental figure 3 displays a box plot assessing the pooled accuracy of HUD to diagnose moderate/severe LVEF (<45%). SROC curves show an improvement in diagnostic accuracy of reduced LVEF, WMA and LV dilatation when performed by experienced users (figure 5). A summary of the meta-analysis data is provided in table 2.


The highest diagnostic ORs were in assessing LV dilatation (DOR 96, 95% CI 40 to 229). This result indicates that the odds of a positive result in a patient with LV dilatation is approximately 96 times higher than the odds for a positive result in a person with no LV dilatation. There was a significant difference in the diagnostic accuracy between experienced and inexperienced users in LV dilatation, LVEF (moderate/severe) and WMA. The DOR for LVEF (moderate/severe), LV dilatation and WMA in an

experienced hand was 276, 225 and 90, respectively, compared with 41, 45 and 28, respectively, for inexperienced users. The total effect sizes and subgroup differences test comparing the HUD parameters in experienced and inexperienced users are shown in online supplemental table 2. A sensitivity analysis excluding studies that visually assessed LVH and LV dilatation showed that quantitative analysis improves the diagnostic accuracy of HUD. Meta-regression analysis confirmed experience to be a significant factor in the detection of any degree of LVEF dysfunction (p=0.04) and WMA (p=0.01) (online supplemental table 3).

Heterogeneity

Heterogeneity can be visualised in all the forest plots depicting sensitivity and in the LVEF and LVH plot depicting specificity. Despite there being some overlap of CIs, sampling variation

LVEF






Figure 2 Meta-analyses of left ventricular ejection fraction (LVEF) and left ventricular (LV) dilatation. Sensitivity and specificity (95% CI) values are reported.

does not completely explain the differences between studies. This apparent heterogeneity can also be observed in the SROC curves for LVEF, WMA and LV dilatation. The increased heterogeneity in the sensitivity plots may be partly explained by fewer patients with the target condition than without. This provides less certainty and results in wider CIs.

A negative correlation between sensitivity and specificity was shown in the meta-analysis of LVEF<45%, WMA and LV dilatation indicating no significant heterogeneity. The correlation coefficients for LVEF (any abnormality) and LVH was positive indicating the presence of possible heterogeneity in the results. We planned to assess the effect of operator experience, pre-existing comorbidities and baseline LV function on the results in a meta-regression covariate analysis. However, only operator experience was sufficiently reported and showed that experience was a significant factor in detecting LVEF, WMA and LV dilatation.


Variation in thresholds likely accounts for some heterogeneity when measuring LVEF (any abnormality), LV dilatation and LVH. Studies with both qualitative and quantitative methodologies were incorporated into the meta-analysis. Quantitative thresholds of LV dilatation ranged from >53 mm to >59 mm, with some studies classifying LV dilatation subject to gender. Similarly, studies measuring LVH were both qualitative and quantitative, with thresholds ranging from >10 mm to >12 mm. A sensitivity analysis excluding qualitative assessment of LVH and LV dilatation showed an improvement in the diagnostic accuracy (online supplemental table 3).

Other sources of heterogeneity may also exist that cannot be assessed including functionality and technological advancement

WMA

Study and Subgroup	Sensitivity	Specificity	Sensitivity	Specificity
Experienced			-	
Cullen 2013	0.60 [0.32; 0.84]	0.95 [0.90; 0.98]		
Fedson 2003		0.90 [0.76; 0.97]		
Khan 2014	0.86 [0.78; 0.92]	0.97 [0.93; 0.99]		
Liebo (expDR) 2011	0.67 [0.35; 0.90]	0.91 [0.82; 0.96]		
Liebo (expMS) 2011	0.82 [0.48; 0.98]	0.94 [0.85; 0.98]		
Vignon 2004	0.90 [0.70; 0.99]	1.00 [0.16; 1.00]	— <u>—</u> —	د ا
Wejner-Mik 2019	0.88 [0.76; 0.95]	0.97 [0.85; 1.00]		
Xie 2006	0.97 [0.85; 1.00]	0.98 [0.92; 1.00]		
Random effects model	0.85 [0.76; 0.91]	0.95 [0.93; 0.96]	-	•
Inexperienced				
Bruce 2002	0.88 [0.79; 0.93]	0.81 [0.62; 0.94]	÷	
Decara (inexp) 2003	0.55 [0.32; 0.77]			
Giusca 2010	0.65 [0.43; 0.84]	0.90 [0.73; 0.98]		
Liebo (inexpML) 2011	0.60 [0.26; 0.88]	0.94 [0.86; 0.98]	<	
Liebo (inexpRI) 2011	0.80 [0.44; 0.97]	0.85 [0.74; 0.92]		
Lucas 2009	0.85 [0.75; 0.92]	0.88 [0.83; 0.92]		
Lucas 2011	0.84 [0.73; 0.92]	0.85 [0.78; 0.91]		
Ruddox 2013	0.76 [0.66; 0.84]	0.88 [0.82; 0.92]		
Random effects model	0.78 [0.70; 0.84]	0.88 [0.85; 0.90]	-	•
Fixed effects (plural) model	0.81 [0.74; 0.85]	0.90 [0.88; 0.92]		· · · · · · · · ·

LV Hypertrophy



05 06 07

Figure 3 Meta-analyses of wall motion abnormality (WMA) and left ventricular hypertrophy (LVH). Sensitivity and specificity (95% CI) values are reported.

of handheld devices that may allow for more accurate results to be obtained. Some studies reported any abnormality in LVEF as a positive finding without quantifying the results into mild, moderate or severe, which may have led to heterogeneity between studies. However, to limit the effect of the possible heterogeneity we analysed studies reporting LVEF <45% (moderate and severe degrees of LV dysfunction) separately. This analysis allowed for a detailed assessment of HUD in significant disease.

Varying levels of experience using HUD by experienced echocardiographers may account for some heterogeneity. The level and volume of training received by non-experienced users prior to each study was also variable adding to heterogeneity within the non-experienced subgroup.

DISCUSSION

To the best of our knowledge, this is the first meta-analysis of the diagnostic accuracy of HUD for imaging LV cardiac structural and functional abnormalities and the first to report the impact of user experience. The meta-analysis shows that HUD is both a sensitive and specific method for assessing LV function and morphology when performed by experienced operators. While a basic competence in HUD can be achieved in a

Jenkins S, et al. Heart 2021;0:1–9. doi:10.1136/heartjnl-2021-319561

relatively short period of time, in clinical practice, a cautious, supervised approach should be applied when inexperienced users are acquiring and interpreting images. This mostly applies to secondary care where the prevalence of disease and the availability of experienced echocardiographers is greatest. Our findings demonstrate that HUD is a valuable bedside tool that can be used to identify those who require further investigation and as a result may lead to a reduction in the number of unnecessary echo referrals (table 3).

Training is required to be able to use HUD competently and therefore the results of our study should be interpreted based on the level of operator experience. The amount of training offered and ability to practise using HUD will also impact the diagnostic outcome that can be expected. Operators with limited training however were less able to detect LV dilatation and WMA, recording pooled sensitivities of 68% and 78%, respectively compared with 89% and 85% achieved by experienced echocardiographers. A positive scan in an experienced hand had a 3–6 times higher odds of showing true LV impairment, LV dilatation or WMA compared with inexperienced operators. Operator experience was not a significant discriminating factor when measuring LVH suggesting that it




Figure 4 Summary receiver operating characteristic curve (SROC) for the pooled sensitivity and specificity with the summary point for the different handheld ultrasound devices assessments. HSROC, hierarchical summary receiver operator curves; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LV, left ventricular; WMA, wall motion abnormality.

can be more accurately measured by clinicians with minimal training.

Important logistical points need to be considered including cost-effectiveness, training and accessibility by clinicians. HUD has been shown to be more cost-effective in comparison to TTE and reduces overall costs when compared with physical examination.⁶ ¹¹ Despite these potential savings, implementation requires training and frequent revalidation to maintain the clinician's skill. Didactic and practical sessions are required before clinicians can achieve basic competence in HUD. A minimum of 30 scans has been recommended, however brief training is associated with an increased false-positive rate.¹² ¹³ This first highlights that HUD performed by inexperienced users should be supervised by experienced echocardiographers as previously mentioned and second, the importance of frequent training and consolidation in echocardiography before allowing users to image patients without supervision. Accessibility of recorded




Figure 5 Summary receiver operating characteristic curves for LV parameters comparing effect user experience on handheld ultrasound devices diagnostic accuracy. LVEF, left ventricular ejection fraction; LV, left ventricular; WMA, wall motion abnormality.

images is therefore a fundamental property of a HUD if sufficient supervision is to be achieved.

Our data suggest that HUD is best positioned at the beginning of the clinical pathway when suspicious of cardiac pathology, thus augmenting the cardiovascular examination. Detecting cardiac disease earlier, when the prevalence of any abnormality is at its lowest, is likely to incur higher rates of false positives. However, HUD should be considered as a method of triaging patients who may require further investigation. HUD should not be considered as a replacement to TTE. HUD can be conducted at the bedside and take <6 min.¹⁴ It can be argued that this is preferable compared with the potential of unnecessarily having to wait for a more complex scan, which may require the patient to return on a separate day or result in a longer stay in hospital. However, a negative finding on HUD and not proceeding to full TTE risks cardiac abnormalities being missed, a factor which should be considered on an individual patient basis.

Negative results (ie, specificity) can be used with reasonable confidence used to determine normal cardiac physiology. However, positive results need to be interpreted with caution, especially when performed by inexperienced HUD users. Clinical decision making should not be solely guided by the interpretation of HUD images, even by experienced echocardiographers. Instead, these results suggest that HUD should act as an initial

Table 2 Results of meta-analyses comparing the diagnostic accuracy of HUD with first-line TTE

HUD compared with TTE

	Total			Experienced			Inexperienc	ed	
Sensitivity %	Studies (n)	Prevalence	Sensitivity (95% Cl)	Studies (n)	Prevalence	Sensitivity (95% Cl)	Studies (n)	Prevalence	Sensitivity (95% CI)
LVEF (any abnormality)	15 (2936)	0.23	86 (80 to 90)	9 (1406)	0.18	88 (81 to 92)	9 (1530)	0.28	83 (71 to 90)
LVEF (moderate/severe)	10 (1611)	0.27	91 (86 to 94)	5 (722)	0.27	93 (89 to 96)	7 (889)	0.27	84 (72 to 92)
WMA	13 (1931)	0.27	81 (74 to 85)	6 (794)	0.26	85 (76 to 91)	7 (1137)	0.28	78 (70 to 84)
LV dilatation	10 (1966)	0.13	73 (59 to 84)	6 (966)	0.17	89 (64 to 97)	6 (1000)	0.09	68 (51 to 81)
LVH	12 (2229)	0.24	83 (73 to 90)	6 (1096)	0.23	85 (72 to 92)	7 (1133)	0.26	80 (61 to 91)
LVEF (any abnormality)	14 (2851)	0.21	91 (87 to 95)	8 (1368)	0.16	96 (90 to 98)	8 (1483)	0.26	89 (81 to 93)
LVEF (moderate/severe)	10 (1611)	0.27	92 (87 to 96)	5 (722)	0.27	96 (87 to 99)	7 (889)	0.27	91 (83 to 95)
WMA	12 (1876)	0.28	90 (88 to 92)	6 (759)	0.27	95 (93 to 96)	6 (1117)	0.28	88 (85 to 90)
LV dilatation	10 (1966)	0.13	95 (94 to 97)	6 (966)	0.17	98 (93 to 99)	6 (1000)	0.09	95 (93 to 96)
LVH	11 (2228)	0.25	90 (82 to 95)	5 (1095)	0.23	91 (82 to 96)	7 (1133)	0.26	87 (67 to 96)

HUD, handheld ultrasound devices; LV, left ventricular; LVEF, LV ejection fraction; LVH, LV dilatation and hypertrophy; TTE, transthoracic echocardiography; WMA, wall motion abnormalities.

diagnostic test to aid decision making on whether further investigation, including TTE, and treatment is required.

Given the excellent sensitivity and specificity particularly seen with more experienced operators, it is likely that the role of HUD will become even more prominent in future clinical practice. We would support earlier teaching and training of HUD and its incorporation into the medical school curriculum, thus providing an important way of ensuring adequate training for all future doctors.

Strengths and limitations

An extensive literature search was performed. No search filters were used revealing results from an unpublished source, thus minimising the risk of publication bias. To limit the effect of any reporting bias, data were carefully extracted from the results of some studies that did not explicitly state sensitivity and specificity values. The search and data extraction were performed by two authors independently to minimise the bias in the review process.

Half of the included studies are >10 years old and improvement in screen technology, image processing and other advancements might play a pivotal role in improving the diagnostic accuracy of HUD.

The lack of a common threshold for WMA, LV dilatation and LVH means the diagnostic performance may vary between centres. Our results do however show that despite variation in thresholds, the specificity of HUD remains $\geq 87\%$ for all characteristics. Even if sensitivity is reduced, the use of HUD as an initial diagnostic tool means diagnosing a condition and determining disease severity is not the aim of this test. Any uncertainty when interpreting the image should result in referral for further investigation. Clinical suspicion of HF and measurement of LV filling pressures is an important indication for echocardiography assessment and would be a valuable bedside tool. Clarius is one of the only scanners on the market capable of pulse-wave Doppler (PWD), permitted by the installation of a liquid heating device which prevents overheating.¹⁵ The current technological capabilities of most HUDs do not include PWD and therefore filling pressures cannot be measured using these devices.¹⁶ We were therefore unable to analyse sufficient data regarding this variable.

Future applications

With advancement of technology, LV border tracking and other methods of automatic, device-generated, quantitative measures of ejection fraction may become routinely available.¹⁷ Incorporation of PWD and continuous-wave Doppler technology into a greater number of available HUDs will also allow for a more extensive range of quantitative cardiovascular assessments to be undertaken at the bedside. Qualitative assessment of valvular heart disease using colour-flow Doppler is available on most HUDs, however is outside the scope of this review. Images may

Review question	Is handheld echocardiography a	ble to accurately diagnose LV d	ysfunction compared with TTE	?
Population	6062 participants aged 65±5 years	with a male predominance of 54%	requiring routine referral for TTE	
Setting	Single centres with access to TTE			
Studies	Studies of diagnostic tests			
Quality of evidence	Majority of studies reported consecu	utive or random sampling, blinding	of assessors and short time betw	veen HUD and TTE imaging (24–28 hours)
Pooled results	Sensitivity (95% CI)		Specificity (95% CI)	
	Experienced	Inexperienced	Experienced	Inexperienced
LVEF (any abnormality)	88 (81 to 92)	83 (71 to 90)	96 (90 to 98)	89 (81 to 93)
LVEF (moderate/severe)	93 (89 to 96)	84 (72 to 92)	96 (87 to 99)	91 (83 to 95)
WMA	85 (76 to 91)	78 (70 to 84)	95 (93 to 96)	88 (85 to 90)
LV dilatation	89 (64 to 97)	68 (51 to 81)	98 (93 to 99)	95 (93 to 96)
LVH	85 (72 to 92)	80 (61 to 91)	91 (82 to 96)	87 (67 to 96)

HUD, handheld ultrasound devices; LV, left ventricular; LVEF, LV ejection fraction; LVH, LV dilatation and hypertrophy; TTE, transthoracic echocardiography; WMA, wall motion abnormalities.

Heart failure and cardiomyopathies

ultimately be sent remotely following acquisition directly to an experienced echocardiographer who can review and interpret images immediately, fast-tracking patients who require further investigation.¹⁸ ¹⁹ Further developments in HUD therefore have the potential to revolutionise the bedside cardiovascular examination.

This study highlights the need to further develop methods to bridge the gap between experienced and inexperienced users. Education and introduction of an ultrasound curriculum for medical students and junior doctors can improve understanding of clinical anatomy, develop basic ultrasound skills and later their diagnostic ability.^{20 21} Formulation of a designated HUD training pathway would allow for standardisation of HUD competencies and provide structure to those wishing to advance their experience using HUDs. These suggestions are limited by the financial burden this would incur as well as a shortfall of clinicians adequately trained using HUDs.

CONCLUSION

This meta-analysis supports the use of HUD as a powerful modality for predicting LV size and systolic function. HUD diagnostic yield is superior when performed by experienced echocardiographers. Images acquired by an inexperienced operator should be done under direct supervision or validated by a more experienced user. This study provides a strong rationale for considering HUD as an auxiliary tool to the physical examination in secondary care, to aid the clinical decision making when considering referral for TTE.

Key messages

What is already known on this subject?

- Handheld cardiac ultrasound device (HUD) offers rapid bedside assessment of cardiac morphology and function.
- The diagnostic accuracy of HUD previously reported has shown heterogeneity between studies and its clinical value has yet to be determined.

What might this study add?

- To the best of our knowledge, this is the first study to perform a meta-analysis evaluating the diagnostic accuracy of HUD devices to detect cardiac dysfunction and the impact of operator experience on test accuracy.
- This study reports that HUD test accuracy is significantly improved when performed by experienced operators.

How might this impact on clinical practice?

- ▶ The clinical utility of HUD is rapidly expanding.
- Augmentation of the physical cardiovascular examination using HUD may improve detection of cardiac size and function at the bedside and lead to a reduction in the number of unnecessary departmental transthoracic echocardiography referrals.
- Image interpretation by inexperienced operators should be confirmed by more experienced echocardiographers before clinical decisions and referral for further imaging are made.

Twitter Samer Alabed @smrabd and Peter Swoboda @pswoboda81

Contributors SJ, SA and PG contributed to the study conception and design. Material preparation, data collection and analysis were performed by SJ, SA and PG. SA performed the meta-analysis of the diagnostic accuracy parameters. All authors contributed to the interpretation of data. The first draft of the manuscript was written by SJ and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. **Funding** This work was funded in part by the Wellcome Trust (215799/Z/19/Z, 214567/Z/18/Z and 205188/Z/16/Z). For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Competing interests PG is an advisor for Pie Medical Imaging and Medis Medical Imaging. JW lists commercial relationships with AstraZeneca, Bayer and Novartis.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Sam Jenkins http://orcid.org/0000-0003-1941-2892 Samer Alabed http://orcid.org/0000-0002-9960-7587 Benoy Nalin Shah http://orcid.org/0000-0001-9681-7311 Roxy Senior http://orcid.org/0000-0001-6579-7039 Vassilios S Vassiliou http://orcid.org/0000-0002-4005-7752

REFERENCES

- 1 Indications for echocardiography.pdf. Available: https://www.bsecho.org/common/ Uploaded%20files/Education/Protocols%20and%20guidelines/Indications%20for% 20echocardiography.pdf [Accessed 19 Feb 2021].
- 2 Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of echocardiography. J Am Soc Echocardiogr 2019;32:1–64.
- 3 Sicari R, Galderisi M, Voigt J-U, *et al*. The use of pocket-size imaging devices: a position statement of the European association of echocardiography. *Eur J Echocardiogr* 2011;12:85–7.
- 4 Wharton G, Steeds R, Allen J, et al. A minimum dataset for a standard adult transthoracic echocardiogram: a guideline protocol from the British Society of echocardiography. *Echo Res Pract* 2015;2:G9–24.
- 5 Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. *Eur Heart J* 2016;37:1428–38.
- 6 Pathan F, Fonseca R, Marwick TH. Usefulness of Hand-Held Ultrasonography as a Gatekeeper to Standard Echocardiography for "Rarely Appropriate" Echocardiography Requests. *Am J Cardiol* 2016;118:1588–92.
- 7 Diagnostic test accuracy (DTA) reviews. Available: https://training.cochrane.org/ diagnostic-test-accuracy-dta-reviews [Accessed 6 Jul 2021].
- 8 Galasko GIW, Lahiri A, Senior R. Portable echocardiography: an innovative tool in screening for cardiac abnormalities in the community. *Eur J Echocardiogr* 2003;4:119–27.
- 9 Bruce CJ, Montgomery SC, Bailey KR, et al. Utility of hand-carried ultrasound devices used by cardiologists with and without significant echocardiographic experience in the cardiology inpatient and outpatient settings. Am J Cardiol 2002;90:1273–5.
- 10 Greaves K, Jeetley P, Hickman M, et al. The use of hand-carried ultrasound in the hospital setting--a cost-effective analysis. J Am Soc Echocardiogr 2005;18:620–5.
- 11 Spencer KT, Kimura BJ, Korcarz CE, *et al*. Focused cardiac ultrasound: recommendations from the American Society of echocardiography. *J Am Soc Echocardiogr* 2013;26:567–81.
- 12 Wilkinson JS, Barake W, Smith C, et al. Limitations of condensed teaching strategies to develop hand-held cardiac ultrasonography skills in internal medicine residents. Can J Cardiol 2016;32:1034–7.
- 13 Stokke TM, Ruddox V, Sarvari SI, et al. Brief group training of medical students in focused cardiac ultrasound may improve diagnostic accuracy of physical examination. J Am Soc Echocardiogr 2014;27:1238–46.
- 14 Hammoudi N, Arangalage D, Boubrit L, *et al.* Ultrasound-based teaching of cardiac anatomy and physiology to undergraduate medical students. *Arch Cardiovasc Dis* 2013;106:487–91.

- 15 Mjolstad OC, Dalen H, Graven T, et al. Routinely adding ultrasound examinations by pocket-sized ultrasound devices improves inpatient diagnostics in a medical department. *Eur J Intern Med* 2012;23:185–91.
- 16 C3 Overview Handheld Curvilinear Ultrasound Scanner Clarius. Available: https:// clarius.com/gb/scanners/c3/ [Accessed 24 May 2021].
- 17 Rykkje A, Carlsen JF, Nielsen MB. Hand-Held ultrasound devices compared with High-End ultrasound systems: a systematic review. *Diagnostics* 2019;9. doi:10.3390/ diagnostics9020061. [Epub ahead of print: 15 06 2019].
- 18 Narula S, Shameer K, Salem Omar AM, et al. Machine-Learning algorithms to Automate morphological and functional assessments in 2D echocardiography. J Am Coll Cardiol 2016;68:2287–95.
- 19 Sengupta PP, Narula N, Modesto K, et al. Feasibility of intercity and trans-atlantic telerobotic remote ultrasound: assessment facilitated by a nondedicated bandwidth connection. JACC Cardiovasc Imaging 2014;7:804–9.
- 20 Boman K, Olofsson M, Berggren P, *et al.* Robot-assisted remote echocardiographic examination and teleconsultation: a randomized comparison of time to diagnosis with standard of care referral approach. *JACC Cardiovasc Imaging* 2014;7:799–803.
- 21 Aldaas OM, Igata S, Raisinghani A, et al. Accuracy of left ventricular ejection fraction determined by automated analysis of handheld echocardiograms: a comparison of experienced and novice examiners. *Echocardiography* 2019;36:2145–51.
- Alexander JH, Peterson ED, Chen AY, et al. Feasibility of point-of-care echocardiography by internal medicine house staff. Am Heart J 2004;147:476–81.
 Andersen GN, Haugen BO, Graven T, et al. Feasibility and reliability of point-of-care
- 23 Andersen Gin, naugen bo, Graven I, et al. reasionity and reliability of point-of-care pocket-sized echocardiography. Eur J Echocardiogr 2011;12:665–70.
 24 Bioi M. Carti C. Dolumou C. Balanci C. Balanci C. Status and St
- Biais M, Carrié C, Delaunay F, et al. Evaluation of a new pocket echoscopic device for focused cardiac ultrasonography in an emergency setting. *Crit Care* 2012;16:R82.
 Coletta C, Da Marshia F, Jacobi M, and D. Bickling G. P. Barting, J. Bartin
- 25 Coletta C, De Marchis E, Lenoli M, *et al*. Reliability of cardiac dimensions and valvular regurgitation assessment by sonographers using hand-carried ultrasound devices. *Eur J Echocardiogr* 2006;7:275–83.
- 26 Cullen MW, Blauwet LA, Vatury OM, et al. Diagnostic capability of comprehensive handheld vs transthoracic echocardiography. Mayo Clin Proc 2014;89:790–8.
- 27 DeCara JM, Lang RM, Koch R, *et al*. The use of small personal ultrasound devices by internists without formal training in echocardiography. *Eur J Echocardiogr* 2003;4:141–7.
- 28 Fedson S, Neithardt G, Thomas P, et al. Unsuspected clinically important findings detected with a small portable ultrasound device in patients admitted to a general medicine service. J Am Soc Echocardiogr 2003;16:901–5.
- 29 Ghani SN, Kirkpatrick JN, Spencer KT, et al. Rapid assessment of left ventricular systolic function in a pacemaker clinic using a hand-carried ultrasound device. J Interv Card Electrophysiol 2006;16:39–43.
- 30 Giusca S, Jurcut R, Ticulescu R, *et al.* Accuracy of handheld echocardiography for bedside diagnostic evaluation in a tertiary cardiology center: comparison with standard echocardiography. *Echocardiography* 2011;28:136–41.
- 31 Gulič TG, Makuc J, Prosen G, et al. Pocket-size imaging device as a screening tool for aortic stenosis. Wien Klin Wochenschr 2016;128:348–53.
- 32 Khan HA, Wineinger NE, Uddin PQ. Can Hospital rounds with pocket echocardiography by cardiologists reduce standard transthoracic echocardiography? *Am J Med* 2014;127:669.e1–669.e7. doi:10.1016/j.amjmed.2014.03.015
- 33 Kirkpatrick JN, Ghani SN, Spencer KT. Hand carried echocardiography screening for LV systolic dysfunction in a pulmonary function laboratory. *Eur J Echocardiogr* 2008;9:381–3. doi:10.1016/j.euje.2007.06.013

- 34 Kobal SL, Trento L, Baharami S, et al. Comparison of effectiveness of handcarried ultrasound to bedside cardiovascular physical examination. Am J Cardiol 2005;96:1002–6.
- 35 Liebo MJ, Israel RL, Lillie EO. Pocket mobile echocardiography: the next-generation stethoscope? A comparison of rapidly acquired PME images to standard TTE. *Ann Intern Med* 2011;155:33–8. doi:10.7326/0003-4819-155-1-201107050-00005
- 36 López-Palmero S, Bolivar-Herrera N, López-Lloret G, et al. Diagnostic utility of handheld ultrasonography as an extension of the physical examination of patients with heart failure. *Rev Clin Esp* 2015;215:204–10.
- 37 Lucas BP, Candotti C, Margeta B, *et al.* Diagnostic accuracy of hospitalist-performed hand-carried ultrasound echocardiography after a brief training program. *J Hosp Med* 2009;4:340–9. doi:10.1002/jhm.438
- 38 Lucas BP, Candotti C, Margeta B, et al. Hand-Carried echocardiography by hospitalists: a randomized trial. Am J Med 2011;124:766–74.
- 39 Martin LD, Howell EE, Ziegelstein RC, et al. Hand-carried ultrasound performed by hospitalists: does it improve the cardiac physical examination? Am J Med 2009;122:35–41.
- 40 Mehta M, Jacobson T, Peters D, et al. Handheld ultrasound versus physical examination in patients referred for transthoracic echocardiography for a suspected cardiac condition. JACC Cardiovasc Imaging 2014;7:983–90.
- 41 Mjølstad OC, Andersen GN, Dalen H, et al. Feasibility and reliability of point-of-care pocket-size echocardiography performed by medical residents. Eur Heart J Cardiovasc Imaging 2013;14:1195–202.
- 42 Nilsson G, Söderström L, Alverlind K, et al. Hand-Held cardiac ultrasound examinations performed in primary care patients by nonexperts to identify reduced ejection fraction. BMC Med Educ 2019;19:282.
- 43 Olesen LL, Andersen A, Thaulow S. Hand-Held echocardiography is useful for diagnosis of left systolic dysfunction in an elderly population. *Dan Med J* 2015;62:A5100.
- 44 Perez-Avraham G, Kobal SL, Etzion O, et al. Left ventricular geometric abnormality screening in hypertensive patients using a hand-carried ultrasound device. J Clin Hypertens 2010;12:181–6.
- 45 Razi R, Estrada JR, Doll J, *et al.* Bedside hand-carried ultrasound by internal medicine residents versus traditional clinical assessment for the identification of systolic dysfunction in patients admitted with decompensated heart failure. *J Am Soc Echocardiogr* 2011;24:1319–24.
- 46 Ruddox V, Stokke TM, Edvardsen T, et al. The diagnostic accuracy of pocket-size cardiac ultrasound performed by unselected residents with minimal training. Int J Cardiovasc Imaging 2013;29:1749–57.
- 47 Vignon P, Frank MBJ, Lesage J, *et al*. Hand-held echocardiography with Doppler capability for the assessment of critically-ill patients: is it reliable? *Intensive Care Med* 2004;30:718–23.
- 48 Vourvouri EC, Schinkel AFL, Roelandt JRTC, et al. Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail 2003;5:767–74.
- 49 Wejner-Mik P, Kasprzak JD, Filipiak-Strzecka D, et al. Personal mobile device-based pocket echocardiograph-The diagnostic value and clinical utility. Adv Med Sci 2019;64:157–61.
- 50 Xie T, Chamoun AJ, McCulloch M, et al. Rapid screening of cardiac patients with a miniaturized hand-held ultrasound imager--comparisons with physical examination and conventional two-dimensional echocardiography. *Clin Cardiol* 2004;27:241–5. doi:10.1002/clc.4960270414

HUD MA Supplementary Material

Search terms used in MA

Medline

5	(handheld OR hand?held OR pocket?siz* OR hand?carried OR mobile OR bed?side OR bedside).ti,ab	141,288
6	(echocardiogram OR echocardiography OR ultrasound).ti,ab	359,331
7	(5 AND 6)	6,198

EMBASE

1	(handheld OR hand?held OR pocket?siz* OR hand?carried OR mobile OR bed?side OR bedside).ti,ab	183,391
2	(echocardiogram OR echocardiography OR ultrasound).ti,ab	580,544
3	(1 AND 2)	11,019

Table 1. Individual study data incorporated into the meta-analysis.

Study	Parameter	Threshold	Whole Sample Size	Total Number Measured	Total Number Positive	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
LVEF									
	LV border	LVEF <50% - At							
Aldaas	detection and	least adequate							
(exp) 2019	tracking	image quality	70	56	8	75	98	N/A	N/A
Aldaas	LV border	LVEF <50% - At							
(inexp)	detection and	least adequate							
2019	tracking	image quality	70	56	8	75	100	100	96
	Visual estimation								
Alexander	of LV systolic								
2004	function	LVEF <55%	537	533	223	82	71	67	85
Andersen	Qualitative	SE>=moderate							
2011	assessment	pathology	108	108	35	97	99	97	99
	Visual estimation								
	of LV systolic								
Biais 2012	function	LVEF <50%	151	151	28	86	99	96	97
Decara	Qualitative								
(exp) 2003	assessment	LV dysfunction	300	149	38	89	N/A	N/A	N/A
Decara									
(inexp)	Qualitative								
2003	assessment	LV dysfunction	300	151	47	97	N/A	N/A	N/A
Fedson	Qualitative								
2003	assessment	>=mild	103	39	11	73	64	44	86
	Visual estimation								
Galasko	of LV systolic								
2003	function	LVEF <50%	562	531	51	96	98	83	99.6
	Visual estimation								
	of LV systolic								
Ghani 2006	function	LVEF <40%	80	73	16	75	91	71	93
Gulic (exp)	Qualitative	Any reduction in							
2016	assessment	LVEF	200	200	22	72	94	64	97
Gulic									
(inexp)	Qualitative	Any reduction in							
2016	assessment	LVEF	200	200	22	84	92	58	98
		Normal >=55%,							
	Visual estimation	moderate 35%-							
	of LV systolic	<55%, severely							
Khan 2014	function	reduced <35%	240	239	70	93	92	84	97

	Visual estimation								
Kirkpatrick	of LV systolic								
2005	function	LVEF <40%	63	63	3	100	83	23	100
	Visual estimation								
	of LV systolic								
Kobal 2005	function	LVEF <50%	61	61	22	86	82	73	91
Liebo	Visual estimation								
(expDR)	of LV systolic								
2011	function	LVEF <45%	97	91	13	85	99	92	97
Liebo	Visual estimation								
(expMS)	of LV systolic								
2011	function	LVEF <45%	97	90	12	92	99	92	99
Liebo	Visual estimation								
(inexpRI)	of LV systolic								
2011	function	LVEF <45%	97	97	13	85	93	65	98
Liebo	Visual estimation								
(inexpML)	of LV systolic								
2011	function	LVEF <45%	97	92	11	73	98	80	96
Lopez-									
Palmero	Qualitative	Normal or							
2015	assessment	depressed	223	212	85	95.2	93.7	91	96.7
Martin	Qualitative	Normal or							
2009	assessment	abnormal	354	336	124	81	92	85	89
Mehta	Qualitative								
2014	assessment	LVEF<40%	250	250	54	96	89	70	99
	Systolic excursion								
	of AV plane and								
	visual estimation								
Mjolstad	of LV systolic	LVEF <45% =							
2013	function	moderate+	199	129	30	92	94	80	98
	Visual estimation								
Nilsson	of LV systolic								
2019	function	LVEF<50%	100	140	19	47	81	28	91
Oleson	Qualitative								
2015	assessment	LVEF<50%	260	255	125	65	83	79	71
	Visual estimation								
	of LV systolic								
Razi 2011	function	LVEF <40%	50	50	33	94	94	97	88
	Visual estimation								
Ruddox	of LV systolic								
2013	function	LVEF<40%	303	283	81	57	92	74	84
Stokke	Visual estimation								
(inexp)	of LV systolic								
2014	function	LVEF <45%	72	105	61	90	57	74	81

Jenkins S, et al. Heart 2021;0:1-9. doi: 10.1136/heartjnl-2021-319561

	Visual estimation								
Stokke	of LV systolic								
(exp) 2014	function	LVEF <45%	72	101	59	92	67	79	85
Vignon	runction		72	101	55	52	07	/5	05
2004	Not specified	Not specified	55	42	22	91	89	91	89
2004	Visual estimation	Not specified	55	42	22	91		91	89
Vourvouri	of LV systolic								
2003	function	LVEF <40%	88	82	19	89	98	94	97
Xie 2006	Not Specified	LVEF<50%	100	100	33	91	99	97	96
WMA									
	Qualitative								
Bruce 2002	assessment	Present	374	124	97	88	82	94	65
	Based on 16-								
Cullen 2013	segment model	Present	190	190	15	60	95	50	97
Decara	Qualitative								
(exp) 2003	assessment	Present	300	149	14	79	N/A	N/A	N/A
Decara									
(inexp)	Qualitative								
2003	assessment	Present	300	151	20	55	N/A	N/A	N/A
Fedson	Qualitative								
2003	assessment	Present	103	39	0	N/A	90	N/A	N/A
Giusca									
2010	Not Specified	Present	56	52	23	65.2	89.5	76.5	83.3
	Lack of normal								
	systolic thickening								
	or translational								
	motion towards								
Khan 2014	centreline	Present	240	232	94	86	97	95	91
	Lack of normal								
	systolic thickening								
Liebo	or translational								
(expDR)	motion towards								
2011	centreline	Present	97	90	15	67	91	53	95
	Lack of normal	-						-	_
	systolic thickening								
Liebo	or translational								
(expMS)	motion towards								
2011	centreline	Present	97	74	11	82	94	69	97
	Lack of normal		-			-			
	systolic thickening								
Liebo	or translational								
(inexpRI)	motion towards								
2011	centreline	Present	97	76	10	80	85	44	97
2011	centrenine	. resent	5,	,,,				1 17	1.27

Jenkins S, et al. Heart 2021;0:1-9. doi: 10.1136/heartjnl-2021-319561

						1			r
	Lack of normal								
	systolic thickening								
Liebo									
(inexpML)									
2011		Present	97	80	10	60	94	60	94
	Abnormal wall								
	movement/thicken								
Lucas 2009	e e i	Present	322	314	80	85	88	71	95
	Abnormal wall								
	movement/thicken								
Lucas 2011	ing during systole	Present	210	210	67	84	85	73	92
Ruddox									
2013	Visual estimation	Present	303	261	96	76	88	79	86
Vignon									
2004	Not specified	Not specified	55	23	21	90	100	100	50
Wejner-Mik									
2019	Visual estimation	Present	87	85	50	88	97	98	86
Xie 2006	Not Specified	Present	100	100	36	97	98	97	98
LV Dilation									
		Yes/No							
	Qualitative	SE=LV dilation							
Biais 2012		>55mm	151	151	8	94	96	57	100
Coletta		Normal	131	131	0	54	50	57	100
2006		30mm/m2	112	105	87	100	65	93	100
Giusca		301111/112	112	105	07	100	05	- 55	100
2010		>59mm	56	52	7	71	100	100	95.7
		23911111	50	52	/	/1	100	100	95.7
Gulic (exp)		Voc/No	200	200	0	4.4	07	50	07
2016 Culia		Yes/No	200	200	9	44	97	50	97
Gulic									
(inexp)		Voc/No	200	200	0	5 5	04	21	00
2016	assessment	Yes/No	200	200	9	55	94	31	98
Kh 2014		>53mm women,	240	225	22	07	00	01	00
Khan 2014	LVEDD	>59mm men	240	225	33	87	98	91	98
	Qualitative	V/NI-							
		Yes/No				67		70	
K-1-10005		-	C 4	C 4	4.2		94	73	92
Kobal 2005	assessment	SE>56mm	61	61	12	67			
Liebo	assessment	SE>56mm	61	61	12	67			
Liebo (expDR)	assessment	SE>56mm >53mm women,							
Liebo (expDR) 2011	assessment LVEDD	SE>56mm	61 97	61 92	12 15	67	99	91	94
Liebo (expDR) 2011 Liebo	assessment LVEDD	SE>56mm >53mm women, >59mm men						91	94
Liebo (expDR) 2011	assessment LVEDD	SE>56mm >53mm women,						91	94

Jenkins S, et al. Heart 2021;0:1-9. doi: 10.1136/heartjnl-2021-319561

Supplemental material

Liebo									
(inexpRI)		>53mm women,	07	02	15	70	05	72	05
2011 Liebo	LVEDD	>59mm men	97	92	15	73	95	73	95
(inexpML)		>53mm women,							
(inexpivit) 2011	LVEDD	>59mm men	97	90	15	53	97	80	91
Lopez-	LVLDD	>55111111111	57	50	15	55	57		51
Palmero		>53mm women,							
2015	LVEDD	>59mm men	223	212	34	94	97	84.2	98.8
Ruddox			-		_	-			
2013	LVEDD	Not specified	303	293	52	46	93	60	89
Xie 2006	LVEDD	LVEDD >=55mm	100	100	19	89	99	94	98
LVH									
								<u> </u>	
	Qualitative	Yes/No					<u> </u>	+	
Biais 2012	assessment	SE=IVS>13mm	151	151	26	77	97	83	95
Coletta									
2006	IVS	Normal 12mm	112	105	82	97	79	94	88
Coletta									
2006	PW	Normal 12mm	112	105	93	97	70	96	74
Decara	Qualitative								
(exp) 2003	assessment	Severe	300	149	1	100	N/A	N/A	N/A
Galasko									
2003	IVS or PW	>=13mm	562	540	31	94	93	45	99.6
Galasko									
2003	IVS or PW	>=12mm	562	540	55	82	96	69	98
	End-diastolic								
c:	thickness of								
Giusca	interventricular	11,000	FC	52	0	FC	100	100	01 5
2010	septum	>=11mm	56	52	9	56	100	100	91.5
Gulic (exp) 2016	Qualitative	Yes/No SE=IVS>14mm	200	200	108	72	75	77	70
Gulic	assessment	3E-1V3/1411111	200	200	100	12	75		70
(inexp)	Qualitative	Yes/No							
2016	assessment	SE=IVS>14mm	200	200	108	83	58	70	75
2010	0556551116112	Yes/No	200	200	100	05	50		75
	Qualitative	SE=IVS/PW>=12m							
Kobal 2005	assessment	m	61	61	23	65	71	58	77
Lopez-									1
Palmero									
2015	IVS or PW	>10mm	223	212	134	96	91	94.8	92.2
	Posterior/septal								
	r osterior/septur					1	1	1	0-
Lucas 2009	wall thickness	>=12mm	322	314	33	70	73	23	95
Lucas 2009		>=12mm >=1.4 (M), >=1.3	322	314	33	70	73 68	23	95 88

Perez-									
Avraham		IVS>=11.7,							
2010	IVS or PW	PW>=9.8	85	85	18	100	99	95	100
		>134gm2/m2							
Senior 2004	LVMI	(M), 110 (F)	189	179	46	72	91	73	90
Vourvouri		>134gm2/m2							
2002	LVMI	(M), 110 (F)	100	100	18	83	96	79	96
	Septal wall								
Xie 2006	thickness	>=12mm	100	100	41	80	93	89	87

We extracted and collated data using a standardised, agreed upon, data extraction form. Data collected included:

- 1. Methods:
 - Study design
 - o Total duration of study
 - o Study setting
 - Date of study
 - Country of study
- 2. Participants:
 - o Number included and analysed for the index and reference test
 - $\circ \quad \text{Mean age} \quad$
 - \circ Gender
 - o Inclusion criteria
 - o Exclusion criteria.
- 3. Index test:
 - Type of HUD
 - Experience of operators
 - o Number of operators
 - o Time between index and reference test
- 4. Reference Standard:
 - Type of standard echocardiography
 - o Experience of operators
 - Number of operators
- 5. Outcomes: LV parameters including function, dilatation, wall motion abnormality and hypertrophy.
- 6. Thresholds:
 - o LVEF
 - Mild = LVEF 45-55%
 - Moderate/severe = LVEF <45%
 - o LV dilatation
 - LVEDD >53mm
 - o WMA
 - Present/absent
 - o LVH
 - Interventricular septum/posterior wall >10mm
- 7. Diagnostic data:

- Sensitivity/specificity/PPV/NPV
- TP/TN/FP/FN
- o Prevalence
- $\circ \quad \text{Total number measured} \quad$

Table 2. Diagnostic odds ratios for HUD cardiac assessment.

Characteristic	DOR Overall (CI)	DOR Experienced (CI)	DOR Inexperienced (CI)	p-value
LVEF (any abnormality)	58.63 (26.11-131.63)	131.24 (37.75-456.22)	28.11 (11.19-70.56)	0.051
LVEF (moderate/severe)	88.55 (38.88-201.68)	276.02 (57.70- 1320.41)	41.45 (18.34-93.72)	0.035
WMA	40.81 (25.19-66.10)	89.97 (30.56-264.86)	28.34 (19.76-40.63)	0.047
LVH	26.69 (11.27-78.25)	54.92 (13.96-216.08)	18.17 (5.05-65.41)	0.248
LVH (quantitative only)	54.69 (11.99-249.45)	96.59 (50.81-183.59)	39.48 (4.81-323.90)	0.436
LV Dilatation	95.81 (40.12-228.85)	224.63 (87.38-577.51)	44.84 (16.38-122.77)	0.022
LV Dilatation (quantitative only)	142.29 (42.94-471.48)	405.51 (143.18- 1148.50)	62.41 (14.30-272.40)	0.042

Table 3. Heterogeneity assessment and evaluation of operator experience on the

diagnostic performance of HUD.

HUD	Heterogeneity Assessment	Operator Experience		
Parameter	Correlation coefficient between log Sp and log SN	Meta-regression covariate coefficient	P value	
LVEF	0.3	-1.64	0.04	
LVEF <40	-0.14	-1.65	0.04	
LV dilatation	-0.39	-0.09	0.88	
LVH	0.39	-1.08	0.31	
WMA	-0.06	-1.055	0.01	

Contrary to intervention meta-analyses, the l² statistic is not a reliable indicator for heterogeneity in diagnostic test accuracy reviews and therefore was not assessed(1). Instead, heterogeneity can be analysed by estimating the correlation between sensitivity and specificity(2). In a normal ROC curve, an increase in sensitivity is offset by a decrease in specificity and therefore they have a negative correlation. A correlation coefficient larger than zero indicates possible heterogeneity. The correlation coefficient of the logit-transformed sensitivity and specificity was calculated for all variables.

The sensitivity and specificity are proportion data and limited between the lower and upper limits of 0 and 1. To apply the correlation statistics and meet its distribution assumption, the proportion data are logit-transformed to release the upper and lower limits of the sensitivity and specificity data(2).

We planned to assess the effect of operator experience, pre-existing comorbidities and baseline LV function on the results in a meta-regression covariate analysis. However, only operator experience was sufficiently reported and showed that experience was a significant factor in detecting LVEF, WMA and LV dilatation.

Heart

Domain	Risk of bias (%)			
Domain	High	Unclear	Low	
Flow and Timing	3	27	70	
Reference Standard	9	15	76	
Index Test	3	15	82	
Patient Selection	0	21	79	




Figure 1. Tabulated and graphical displays for QUADAS-2 results.

The risk of bias was qualitatively assessed based on the domains of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Parameters evaluated included random or consecutive recruitment of patients (patient sampling), blinding of assessors to index and reference test, and the time between HUD and TTE (flow and timing). Two reviewers (SJ and PG) independently assessed the risk of bias for each study with disagreements discussed with a third author (SA). Studies categorised as low for all domains were regarded as having a low risk of bias Studies stated as being high or unclear in \geq 1 domain were judged to be at risk of bias.




Figure 2. Risk of bias summary for each included study

LVEF <45% (moderate/severe dysfunction)




Figure 3. Meta-analyses of LVEF <45%. Sensitivity and specificity [CI] values are

reported.

The bivariate method was used to calculated overall sensitivity and specificity and their 95% confidence intervals. The summary estimates of sensitivity and specificity using this method represent the average operating point across studies. The bivariate nature of the input data is maintained throughout the analysis using the bivariate model which allows the calculation of reliable summary estimates. Other advantages of the bivariate method include accounting for the study size, betweenstudy heterogeneity and adjusting for the threshold effect seen when there is a negative correlation between the sensitivity and the specificity of the index test(3).

References

- 1. Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. :61.
- Shim SR, Kim S-J, Lee J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health [Internet]. 2019 Mar 28 [cited 2021 Mar 26];41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545496/
- 3. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005 Oct;58(10):982–90.